<div id="readability-page-1"><div>TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Theravance Biopharma, Inc. (“Theravance” or “the Company”) (NASDAQ: TBPH) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Theravance reported spending millions of dollars on operations expenses while its CYPRESS trial was in the enrollment phase, representing a major cash burn on a high-risk program. The Company’s trial ultimately failed. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA0MDIyNTEwNTdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA0MDIyNTEwNTdyMQ"/> The Schall Law Firm Brian Schall, Esq. 310-301-3335 info@schallfirm.com www.schallfirm.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260402251057/en/</div></div>

Theravance生物制药

Schall 律师事务所正在代表 Theravance Biopharma, Inc.（纳斯达克股票代码：TBPH）的投资者调查潜在的证券法违规行为。调查的重点是该公司是否发布了虚假或误导性声明，并未披露关键信息。据报道，Theravance 在其 CYPRESS 试验中产生了重大运营费用，而该试验最终失败。遭受损失的股东被鼓励参与调查，并可以联系 Schall 律师事务所以获取更多信息

Theravance 生物制药公司的投资者有机会与 Schall 律师事务所合作，参与该公司的欺诈调查